Literature DB >> 28213937

Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

Sevil Korkmaz-Icöz1, Tamás Radovits2, Gábor Szabó1.   

Abstract

Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5'-GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP-dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5 inhibitors, may represent an effective therapeutic approach. There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. Sildenafil and tadalafil have also received Food and Drug Administration approval for the treatment of pulmonary arterial hypertension. This review summarizes the pharmacological aspects and clinical potential of PDE5 inhibition for the treatment of myocardial ischaemia/reperfusion injury and heart failure. LINKED ARTICLES: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
© 2017 The British Pharmacological Society.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28213937      PMCID： PMC5758391          DOI： 10.1111/bph.13749

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  76 in total

1.  Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity.

Authors:  Kyung-Hee Kim; Yong-Jin Kim; Jung-Hun Ohn; Jimin Yang; Sang-Eun Lee; Sae-Won Lee; Hyung-Kwan Kim; Jeong-Wook Seo; Dae-Won Sohn
Journal:  Circulation       Date:  2012-02-08       Impact factor: 29.690

Review 2.  Overview of PDEs and their regulation.

Authors:  Kenji Omori; Jun Kotera
Journal:  Circ Res       Date:  2007-02-16       Impact factor: 17.367

3.  Oxidative stress regulates left ventricular PDE5 expression in the failing heart.

Authors:  Zhongbing Lu; Xin Xu; Xinli Hu; Sangjin Lee; Jay H Traverse; Guangshuo Zhu; John Fassett; Yi Tao; Ping Zhang; Cris dos Remedios; Marc Pritzker; Jennifer L Hall; Daniel J Garry; Yingjie Chen
Journal:  Circulation       Date:  2010-03-22       Impact factor: 29.690

4.  Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.

Authors:  Alice Behling; Luis E Rohde; Fernanda C Colombo; Livia A Goldraich; Ricardo Stein; Nadine Clausell
Journal:  J Card Fail       Date:  2008-04       Impact factor: 5.712

5.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

6.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

7.  Long-term use of sildenafil in the therapeutic management of heart failure.

Authors:  Marco Guazzi; Michele Samaja; Ross Arena; Marco Vicenzi; Maurizio D Guazzi
Journal:  J Am Coll Cardiol       Date:  2007-11-13       Impact factor: 24.094

8.  Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

Authors:  Peter Pokreisz; Sara Vandenwijngaert; Virginie Bito; An Van den Bergh; Ilse Lenaerts; Cornelius Busch; Glenn Marsboom; Olivier Gheysens; Pieter Vermeersch; Liesbeth Biesmans; Xiaoshun Liu; Hilde Gillijns; Marijke Pellens; Alfons Van Lommel; Emmanuel Buys; Luc Schoonjans; Johan Vanhaecke; Erik Verbeken; Karin Sipido; Paul Herijgers; Kenneth D Bloch; Stefan P Janssens
Journal:  Circulation       Date:  2009-01-12       Impact factor: 29.690

9.  Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs.

Authors:  Orsolya Nagy; Agnes Hajnal; James R Parratt; Agnes Végh
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

10.  Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice.

Authors:  Fadi N Salloum; Antonio Abbate; Anindita Das; Jon-Erik Houser; Colin A Mudrick; Ian Z Qureshi; Nicholas N Hoke; Sion K Roy; William R Brown; Shashi Prabhakar; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-25       Impact factor: 4.733
View more
  4 in total

Review 1.  Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

Authors:  Sevil Korkmaz-Icöz; Tamás Radovits; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

2.  Inventing new therapies without reinventing the wheel: the power of drug repurposing.

Authors:  Andreas Papapetropoulos; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2018-01       Impact factor: 8.739

Review 3.  PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery.

Authors:  K-E Andersson
Journal:  Br J Pharmacol       Date:  2018-04-25       Impact factor: 8.739

4.  Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems.

Authors:  Jo-Fan Chang; Jui-Ling Hsu; Yi-Hua Sheng; Wohn-Jenn Leu; Chia-Chun Yu; She-Hung Chan; Mei-Ling Chan; Lih-Ching Hsu; Shih-Ping Liu; Jih-Hwa Guh
Journal:  Front Oncol       Date:  2019-01-17       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.